ITM, Debiopharm image first patient in phase I/II ITM-94 trial

ITM Isotope Technologies Munich SE (ITM) and Debiopharm have imaged the first patient in a phase I/II trial evaluating ITM-94 as a diagnostic agent for clear cell renal cell carcinoma (ccRCC).

The trial will also evaluate ITM-94's effectiveness for classifying indeterminate renal mass as either ccRCC or noncancerous. ITM-91/ITM-94 is a peptide-based theranostic pair that combines ITM-91 (Debio 0228, or Lu-177 Lu-DPI-4452) with the diagnostic agent ITM-94 (Debio 0328, or Ga-68 Ga-DPI-4452) to target carbonic anhydrase IX (CAIX). 

ITM-91/ITM-94 is an investigational theranostic pair originally discovered by 3B Pharmaceuticals GmbH and now exclusively licensed to ITM, the company said.